Abstract | BACKGROUND: METHODS: We have developed a double transgenic mouse model (MET) that forms spontaneous pancreatic tumors and expresses the human MUC1 antigen. Seven-week-old MET mice (n = 8) were treated every 3 weeks with the vaccine. In addition, these mice received 50 microg of superantigen staphylococcal enterotoxin B (SEB), a known T cell stimulant, prior to the first vaccination. A second treatment group received SEB alone (n = 8) and controls received no treatment (n = 9). MUC1-specific CTLs were measured by chromium release assay. At 10 weeks of age and at necropsy, MUC1 serum levels were measured using a MUC1-specific ELISA. RESULTS: Mice were known to harbor microscopic foci of cancer at birth. Survival was enhanced in vaccine as well as SEB-treated mice (75% CI +/- 0.42) compared to controls (11% CI +/- 0.28) and both groups of treated mice exhibited mature CTLs without in vitro stimulation. MUC1 serum levels of the vaccine group were 50% less than that of control (P < 0.04) at 10 weeks. MUC1 serum levels directly correlated with tumor weight at necropsy (r = 0.86). CONCLUSIONS: This is the first evidence that MUC1-specific CTLs can be stimulated to enhance survival in a spontaneous tumor model.
|
Authors | Elizabeth J McConnell, Latha B Pathangey, Cathy S Madsen, Sandra J Gendler, Pinku Mukherjee |
Journal | The Journal of surgical research
(J Surg Res)
Vol. 107
Issue 2
Pg. 196-202
(Oct 2002)
ISSN: 0022-4804 [Print] United States |
PMID | 12429175
(Publication Type: Journal Article)
|
Chemical References |
- Cancer Vaccines
- Enterotoxins
- Mucin-1
- enterotoxin B, staphylococcal
|
Topics |
- Animals
- Cancer Vaccines
(therapeutic use)
- Cell Fusion
- Dendritic Cells
(immunology)
- Disease Models, Animal
- Enterotoxins
(pharmacology)
- Immunization
- Immunotherapy
- Mice
- Mice, Inbred C57BL
- Mucin-1
(blood, immunology)
- Pancreatic Neoplasms
(immunology, pathology, therapy)
- T-Lymphocytes, Cytotoxic
(immunology)
- Tumor Cells, Cultured
|